AustralieFrV1, Ncbi, Curation, bibRecord, 002F62

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Identifieur interne : 002F62 ( Ncbi/Curation ); précédent : 002F61; suivant : 002F63

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Auteurs : N. Raje ; S. Vadhan-Raj [États-Unis] ; W. Willenbacher [Autriche] ; E. Terpos [Grèce] ; V. Hungria [Brésil] ; A. Spencer [Australie] ; Y. Alexeeva [Russie] ; T. Facon [France] ; A K Stewart [États-Unis] ; A. Feng [États-Unis] ; A. Braun [États-Unis] ; A. Balakumaran [États-Unis] ; G D Roodman [États-Unis]

Source :

Blood Cancer Journal [ 2044-5385 ] ; 2016.

RBID : PMC:4742634

Descripteurs français

KwdFr :
- Adulte d'âge moyen, Agents de maintien de la densité osseuse (usage thérapeutique), Diphosphonates (administration et posologie), Diphosphonates (effets indésirables), Diphosphonates (usage thérapeutique), Dénosumab (administration et posologie), Dénosumab (effets indésirables), Dénosumab (usage thérapeutique), Femelle, Humains, Imidazoles (administration et posologie), Imidazoles (effets indésirables), Imidazoles (usage thérapeutique), Myélome multiple (diagnostic), Myélome multiple (mortalité), Myélome multiple (traitement médicamenteux), Mâle, Métastase tumorale, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Transplantation autologue, Transplantation de cellules souches hématopoïétiques, Tumeurs (anatomopathologie), Tumeurs osseuses (secondaire), Tumeurs osseuses (traitement médicamenteux).
MESH :
- administration et posologie : Diphosphonates, Dénosumab, Imidazoles.
- anatomopathologie : Tumeurs.
- diagnostic : Myélome multiple.
- effets indésirables : Diphosphonates, Dénosumab, Imidazoles.
- mortalité : Myélome multiple.
- secondaire : Tumeurs osseuses.
- traitement médicamenteux : Myélome multiple, Tumeurs osseuses.
- usage thérapeutique : Agents de maintien de la densité osseuse, Diphosphonates, Dénosumab, Imidazoles, Protocoles de polychimiothérapie antinéoplasique.
- Adulte d'âge moyen, Femelle, Humains, Mâle, Métastase tumorale, Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Transplantation autologue, Transplantation de cellules souches hématopoïétiques.

English descriptors

KwdEn :
- Aged, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bone Density Conservation Agents (therapeutic use), Bone Neoplasms (drug therapy), Bone Neoplasms (secondary), Denosumab (administration & dosage), Denosumab (adverse effects), Denosumab (therapeutic use), Diphosphonates (administration & dosage), Diphosphonates (adverse effects), Diphosphonates (therapeutic use), Female, Hematopoietic Stem Cell Transplantation, Humans, Imidazoles (administration & dosage), Imidazoles (adverse effects), Imidazoles (therapeutic use), Male, Middle Aged, Multiple Myeloma (diagnosis), Multiple Myeloma (drug therapy), Multiple Myeloma (mortality), Neoplasm Metastasis, Neoplasm Staging, Neoplasms (pathology), Transplantation, Autologous, Treatment Outcome.
MESH :
- chemical , administration & dosage : Denosumab, Diphosphonates, Imidazoles.
- chemical , adverse effects : Denosumab, Diphosphonates, Imidazoles.
- chemical , therapeutic use : Bone Density Conservation Agents, Denosumab, Diphosphonates, Imidazoles.
- diagnosis : Multiple Myeloma.
- drug therapy : Bone Neoplasms, Multiple Myeloma.
- mortality : Multiple Myeloma.
- pathology : Neoplasms.
- secondary : Bone Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Transplantation, Autologous, Treatment Outcome.

Abstract

In a phase 3 trial of denosumab vs zoledronic acid in patients (n=1776) with bone metastases and solid tumors or multiple myeloma, denosumab was superior to zoledronic acid for the primary end point of prevention of skeletal-related events. There was no difference in overall survival between the two groups; however, an ad hoc overall survival analysis in the multiple myeloma subset of patients (n=180) favored zoledronic acid (hazard ratio (HR) 2.26; 95% confidence interval (CI) 1.13–4.50; P=0.014). In the present analysis, we found imbalances between the groups with respect to baseline risk characteristics. HRs with two-sided 95% CIs were estimated using the Cox model. After adjustment in a covariate analysis, the CI crossed unity (HR 1.86; 95% CI 0.90–3.84; P=0.0954). Furthermore, we found a higher rate of early withdrawals for the reasons of lost to follow-up and withdrawal of consent in the zoledronic acid group; after accounting for these, the HR was 1.31 (95% CI 0.80–2.15; P=0.278). In conclusion, the survival results in multiple myeloma patients in this trial were confounded and will eventually be resolved by an ongoing phase 3 trial.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742634

DOI: 10.1038/bcj.2015.96
PubMed: 26745852
PubMed Central: 4742634

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000702
to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000701
to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000963
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002488
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002437
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002437
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002F62

Links to Exploration step

PMC:4742634

Curation

No country items

N. Raje

<affiliation><nlm:aff id="aff1"><institution>Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center</institution>
,<country>Boston</country>
, MA,<country>USA</country>
</nlm:aff>
<wicri:noCountry code="nlm country">Boston</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial</title>
<author><name sortKey="Raje, N" sort="Raje, N" uniqKey="Raje N" first="N" last="Raje">N. Raje</name>
<affiliation><nlm:aff id="aff1"><institution>Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center</institution>
,<country>Boston</country>
, MA,<country>USA</country>
</nlm:aff>
<wicri:noCountry code="nlm country">Boston</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Vadhan Raj, S" sort="Vadhan Raj, S" uniqKey="Vadhan Raj S" first="S" last="Vadhan-Raj">S. Vadhan-Raj</name>
<affiliation wicri:level="1"><nlm:aff id="aff2"><institution>University of Texas, MD Anderson Cancer Center</institution>
, Houston, TX,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Willenbacher, W" sort="Willenbacher, W" uniqKey="Willenbacher W" first="W" last="Willenbacher">W. Willenbacher</name>
<affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Internal Medicine V, Haematology and Oncology, Medical University of Innsbruck</institution>
, Innsbruck,<country>Austria</country>
</nlm:aff>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Terpos, E" sort="Terpos, E" uniqKey="Terpos E" first="E" last="Terpos">E. Terpos</name>
<affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine</institution>
, Athens,<country>Greece</country>
</nlm:aff>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hungria, V" sort="Hungria, V" uniqKey="Hungria V" first="V" last="Hungria">V. Hungria</name>
<affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Irmandade da Santa Casa de Misericordia de Sao Paulo</institution>
, São Paulo,<country>Brazil</country>
</nlm:aff>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Spencer, A" sort="Spencer, A" uniqKey="Spencer A" first="A" last="Spencer">A. Spencer</name>
<affiliation wicri:level="1"><nlm:aff id="aff6"><institution>The Alfred Hospital</institution>
, Melbourne, Victoria,<country>Australia</country>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Alexeeva, Y" sort="Alexeeva, Y" uniqKey="Alexeeva Y" first="Y" last="Alexeeva">Y. Alexeeva</name>
<affiliation wicri:level="1"><nlm:aff id="aff7"><institution>City Hospital No. 31</institution>
, Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Facon, T" sort="Facon, T" uniqKey="Facon T" first="T" last="Facon">T. Facon</name>
<affiliation wicri:level="1"><nlm:aff id="aff8"><institution>Hôpital Claude Huriez</institution>
, Lille,<country>France</country>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Stewart, A K" sort="Stewart, A K" uniqKey="Stewart A" first="A K" last="Stewart">A K Stewart</name>
<affiliation wicri:level="1"><nlm:aff id="aff9"><institution>Mayo Clinic</institution>
, Scottsdale, AZ,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, A" sort="Feng, A" uniqKey="Feng A" first="A" last="Feng">A. Feng</name>
<affiliation wicri:level="1"><nlm:aff id="aff10"><institution>Amgen Inc.</institution>
, Thousand Oaks, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Braun, A" sort="Braun, A" uniqKey="Braun A" first="A" last="Braun">A. Braun</name>
<affiliation wicri:level="1"><nlm:aff id="aff10"><institution>Amgen Inc.</institution>
, Thousand Oaks, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Balakumaran, A" sort="Balakumaran, A" uniqKey="Balakumaran A" first="A" last="Balakumaran">A. Balakumaran</name>
<affiliation wicri:level="1"><nlm:aff id="aff10"><institution>Amgen Inc.</institution>
, Thousand Oaks, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Roodman, G D" sort="Roodman, G D" uniqKey="Roodman G" first="G D" last="Roodman">G D Roodman</name>
<affiliation wicri:level="1"><nlm:aff id="aff11"><institution>Indiana University School of Medicine</institution>
, Indianapolis, IN,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">26745852</idno>
<idno type="pmc">4742634</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742634</idno>
<idno type="RBID">PMC:4742634</idno>
<idno type="doi">10.1038/bcj.2015.96</idno>
<date when="2016">2016</date>
<idno type="wicri:Area/Pmc/Corpus">000702</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000702</idno>
<idno type="wicri:Area/Pmc/Curation">000701</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000701</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000963</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000963</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">002488</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002488</idno>
<idno type="wicri:Area/PubMed/Curation">002437</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002437</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002437</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002437</idno>
<idno type="wicri:Area/Ncbi/Merge">002F62</idno>
<idno type="wicri:Area/Ncbi/Curation">002F62</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial</title>
<author><name sortKey="Raje, N" sort="Raje, N" uniqKey="Raje N" first="N" last="Raje">N. Raje</name>
<affiliation><nlm:aff id="aff1"><institution>Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center</institution>
,<country>Boston</country>
, MA,<country>USA</country>
</nlm:aff>
<wicri:noCountry code="nlm country">Boston</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Vadhan Raj, S" sort="Vadhan Raj, S" uniqKey="Vadhan Raj S" first="S" last="Vadhan-Raj">S. Vadhan-Raj</name>
<affiliation wicri:level="1"><nlm:aff id="aff2"><institution>University of Texas, MD Anderson Cancer Center</institution>
, Houston, TX,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Willenbacher, W" sort="Willenbacher, W" uniqKey="Willenbacher W" first="W" last="Willenbacher">W. Willenbacher</name>
<affiliation wicri:level="1"><nlm:aff id="aff3"><institution>Internal Medicine V, Haematology and Oncology, Medical University of Innsbruck</institution>
, Innsbruck,<country>Austria</country>
</nlm:aff>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Terpos, E" sort="Terpos, E" uniqKey="Terpos E" first="E" last="Terpos">E. Terpos</name>
<affiliation wicri:level="1"><nlm:aff id="aff4"><institution>Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine</institution>
, Athens,<country>Greece</country>
</nlm:aff>
<country xml:lang="fr">Grèce</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hungria, V" sort="Hungria, V" uniqKey="Hungria V" first="V" last="Hungria">V. Hungria</name>
<affiliation wicri:level="1"><nlm:aff id="aff5"><institution>Irmandade da Santa Casa de Misericordia de Sao Paulo</institution>
, São Paulo,<country>Brazil</country>
</nlm:aff>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Spencer, A" sort="Spencer, A" uniqKey="Spencer A" first="A" last="Spencer">A. Spencer</name>
<affiliation wicri:level="1"><nlm:aff id="aff6"><institution>The Alfred Hospital</institution>
, Melbourne, Victoria,<country>Australia</country>
</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Alexeeva, Y" sort="Alexeeva, Y" uniqKey="Alexeeva Y" first="Y" last="Alexeeva">Y. Alexeeva</name>
<affiliation wicri:level="1"><nlm:aff id="aff7"><institution>City Hospital No. 31</institution>
, Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Facon, T" sort="Facon, T" uniqKey="Facon T" first="T" last="Facon">T. Facon</name>
<affiliation wicri:level="1"><nlm:aff id="aff8"><institution>Hôpital Claude Huriez</institution>
, Lille,<country>France</country>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Stewart, A K" sort="Stewart, A K" uniqKey="Stewart A" first="A K" last="Stewart">A K Stewart</name>
<affiliation wicri:level="1"><nlm:aff id="aff9"><institution>Mayo Clinic</institution>
, Scottsdale, AZ,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Feng, A" sort="Feng, A" uniqKey="Feng A" first="A" last="Feng">A. Feng</name>
<affiliation wicri:level="1"><nlm:aff id="aff10"><institution>Amgen Inc.</institution>
, Thousand Oaks, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Braun, A" sort="Braun, A" uniqKey="Braun A" first="A" last="Braun">A. Braun</name>
<affiliation wicri:level="1"><nlm:aff id="aff10"><institution>Amgen Inc.</institution>
, Thousand Oaks, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Balakumaran, A" sort="Balakumaran, A" uniqKey="Balakumaran A" first="A" last="Balakumaran">A. Balakumaran</name>
<affiliation wicri:level="1"><nlm:aff id="aff10"><institution>Amgen Inc.</institution>
, Thousand Oaks, CA,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Roodman, G D" sort="Roodman, G D" uniqKey="Roodman G" first="G D" last="Roodman">G D Roodman</name>
<affiliation wicri:level="1"><nlm:aff id="aff11"><institution>Indiana University School of Medicine</institution>
, Indianapolis, IN,<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Blood Cancer Journal</title>
<idno type="eISSN">2044-5385</idno>
<imprint><date when="2016">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Bone Density Conservation Agents (therapeutic use)</term>
<term>Bone Neoplasms (drug therapy)</term>
<term>Bone Neoplasms (secondary)</term>
<term>Denosumab (administration & dosage)</term>
<term>Denosumab (adverse effects)</term>
<term>Denosumab (therapeutic use)</term>
<term>Diphosphonates (administration & dosage)</term>
<term>Diphosphonates (adverse effects)</term>
<term>Diphosphonates (therapeutic use)</term>
<term>Female</term>
<term>Hematopoietic Stem Cell Transplantation</term>
<term>Humans</term>
<term>Imidazoles (administration & dosage)</term>
<term>Imidazoles (adverse effects)</term>
<term>Imidazoles (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Multiple Myeloma (diagnosis)</term>
<term>Multiple Myeloma (drug therapy)</term>
<term>Multiple Myeloma (mortality)</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Staging</term>
<term>Neoplasms (pathology)</term>
<term>Transplantation, Autologous</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Agents de maintien de la densité osseuse (usage thérapeutique)</term>
<term>Diphosphonates (administration et posologie)</term>
<term>Diphosphonates (effets indésirables)</term>
<term>Diphosphonates (usage thérapeutique)</term>
<term>Dénosumab (administration et posologie)</term>
<term>Dénosumab (effets indésirables)</term>
<term>Dénosumab (usage thérapeutique)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Imidazoles (administration et posologie)</term>
<term>Imidazoles (effets indésirables)</term>
<term>Imidazoles (usage thérapeutique)</term>
<term>Myélome multiple (diagnostic)</term>
<term>Myélome multiple (mortalité)</term>
<term>Myélome multiple (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Résultat thérapeutique</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Transplantation autologue</term>
<term>Transplantation de cellules souches hématopoïétiques</term>
<term>Tumeurs (anatomopathologie)</term>
<term>Tumeurs osseuses (secondaire)</term>
<term>Tumeurs osseuses (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Denosumab</term>
<term>Diphosphonates</term>
<term>Imidazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Denosumab</term>
<term>Diphosphonates</term>
<term>Imidazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bone Density Conservation Agents</term>
<term>Denosumab</term>
<term>Diphosphonates</term>
<term>Imidazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diphosphonates</term>
<term>Dénosumab</term>
<term>Imidazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Multiple Myeloma</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Myélome multiple</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term>
<term>Multiple Myeloma</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diphosphonates</term>
<term>Dénosumab</term>
<term>Imidazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Multiple Myeloma</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Myélome multiple</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs osseuses</term>
</keywords>
<keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Myélome multiple</term>
<term>Tumeurs osseuses</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents de maintien de la densité osseuse</term>
<term>Diphosphonates</term>
<term>Dénosumab</term>
<term>Imidazoles</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Hematopoietic Stem Cell Transplantation</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasm Metastasis</term>
<term>Neoplasm Staging</term>
<term>Transplantation, Autologous</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Métastase tumorale</term>
<term>Résultat thérapeutique</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Transplantation autologue</term>
<term>Transplantation de cellules souches hématopoïétiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>In a phase 3 trial of denosumab vs zoledronic acid in patients (<italic>n</italic>
=1776) with bone metastases and solid tumors or multiple myeloma, denosumab was superior to zoledronic acid for the primary end point of prevention of skeletal-related events. There was no difference in overall survival between the two groups; however, an <italic>ad hoc</italic>
 overall survival analysis in the multiple myeloma subset of patients (<italic>n</italic>
=180) favored zoledronic acid (hazard ratio (HR) 2.26; 95% confidence interval (CI) 1.13–4.50; <italic>P</italic>
=0.014). In the present analysis, we found imbalances between the groups with respect to baseline risk characteristics. HRs with two-sided 95% CIs were estimated using the Cox model. After adjustment in a covariate analysis, the CI crossed unity (HR 1.86; 95% CI 0.90–3.84; <italic>P</italic>
=0.0954). Furthermore, we found a higher rate of early withdrawals for the reasons of lost to follow-up and withdrawal of consent in the zoledronic acid group; after accounting for these, the HR was 1.31 (95% CI 0.80–2.15; <italic>P</italic>
=0.278). In conclusion, the survival results in multiple myeloma patients in this trial were confounded and will eventually be resolved by an ongoing phase 3 trial.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F62 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002F62 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:4742634
   |texte=   Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:26745852" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki